Concurrent Chemoradiotherapy with Docetaxel for T2N0 Laryngeal Carcinoma

• Uno Masako

  Kawasaki Medical School

• Morita Norimasa

  Kawasaki Medical School

• Fukushima Hisaki

  Kawasaki Medical School

• Fujisaki Tomoya

  Kawasaki Medical School

• Tadokoro Hiroaki

  Kawasaki Medical School

• Harada Tamotsu

  Kawasaki Medical School

Bibliographic Information

Other Title

• 喉頭癌T2N0症例に対する化学放射線治療の検討
• コウトウ ガン T2N0 ショウレイ ニ タイスル カガク ホウシャセン チリョウ ノ ケントウ

Abstract

A combination of docetaxel (DOC) therapy and radiotherapy was used to treat patients with T2N0 laryngeal carcinoma. Thirty-two patients with T2N0 laryngeal cancer received concurrent chemoradiotherapy (64.6–74 Gy) with weekly DOC (10 mg/m²). All the patients were male, and their average age was 66.3 years. All the patients achieved a complete response (CR). The overall survival rate, as determined using the Kaplan-Meier method, was 92.0%, and the disease-free survival rate was 92.2%. The local control rates were 88.0% for the glottis and 28.6% for the supraglottis and subglottis. Grade 3 or higher toxicities were seen in 4 patients. In conclusion, concurrent chemoradiotherapy with DOC is a feasible and effective treatment for glottic squamous cell carcinoma.

Journal

• Practica oto-rhino-laryngologica. Suppl.

  Practica oto-rhino-laryngologica. Suppl. 149 (0), 198-202, 2017

  The Society of Practical Otolaryngology

Keywords

• docetaxel
• T2N0 laryngeal carcinoma
• chemoradiotherapy

Details

• CRID: 1390001204328819840
• NII Article ID: 130005529831
• NII Book ID: AN10020883
• DOI: 10.5631/jibirinsuppl.149.198
• ISSN: 21851557
• ISSN: 09121870
• NDL BIB ID: 028140187
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I028140187
• Web Site: https://www.jstage.jst.go.jp/article/jibirinsuppl/149/0/149_198/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2017274433
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed